Results 71 to 80 of about 554,589 (315)
Cabergoline-induced mania in a patient of pituitary microadenoma
Indian Journal of Psychological Medicine, 2017 Cabergoline, a dopamine agonist agent, is commonly used in the treatment of hyperprolactinemia, Parkinson's disease, restless leg syndrome, and antipsychotic-induced prolactin elevation.
Satyakam Mohapatra, Mihir Ranjan Nayak
doaj +1 more source
Molecular ImagingPurpose Elevated dopamine synthesis capacity is part of the pathophysiology of schizophrenia thought to underlie psychosis. Drugs that reduce this phenomenon could thus be potential treatments for these disorders.
David R. Bonsall PhD +13 more
doaj +1 more source
Potential mechanisms for imperfect synchronization in parkinsonian basal ganglia [PDF]
PLoS One. 2012; 7(12): e51530, 2012 Neural activity in the brain of parkinsonian patients is characterized by the intermittently synchronized oscillatory dynamics. This imperfect synchronization, observed in the beta frequency band, is believed to be related to the hypokinetic motor symptoms of the disorder. Our study explores potential mechanisms behind this intermittent synchrony.
arxiv +1 more source
A normative theory of social conflict [PDF]
arXiv, 2023 Social hierarchy in animal groups carries a crucial adaptive function by reducing conflict and injury while protecting valuable group resources. Social hierarchy is dynamic and can be altered by social conflict, agonistic interactions, and aggression.
arxiv
Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes
Diabetes Care, 2011 Bromocriptine is a sympatholytic D2-dopamine agonist that has been approved for the treatment of type 2 diabetes. Based on animal and human studies, timed bromocriptine administration within 2 h of awakening is believed to augment low hypothalamic ...
R. DeFronzo
semanticscholar +1 more source
Frontiers in Human Neuroscience, 2011 We investigated the effect of bromocriptine, a dopamine agonist, on individual differences in behavior as well as frontal–striatal connectivity during a working memory task.
Deanna L. Wallace +4 more
semanticscholar +1 more source
Structure of a D2 dopamine receptor-G protein complex in a lipid membrane
Nature, 2020 The D2 dopamine receptor (DRD2) is a therapeutic target for Parkinson’s disease 1 and antipsychotic drugs 2 . DRD2 is activated by the endogenous neurotransmitter dopamine and synthetic agonist drugs such as bromocriptine 3 , leading to stimulation of G ...
Jie Yin +8 more
semanticscholar +1 more source
Deciphering the skeletal interoceptive circuitry to control bone homeostasis
BMEMat, EarlyView.This review introduces the skeletal interoceptive circuitry, covering the ascending signals from bone tissues to the brain (sensors), the central neural circuits that integrate this information and dispatch commands (CPU), and the descending pathways that regulate bone homeostasis (effectors).
Yefeng Wu +7 more
wiley +1 more source
Pergolide Mesilate May Improve Fatigue in Patients with Parkinson’s Disease
Behavioural Neurology, 2002 Objectives: Fatigue is a complaint frequently encountered among patients with Parkinson’s disease (PD). Considering the possible relationship between fatigue and dopaminergic dysfuncion, we investigated the effect of pergolide mesilate (a D2 and D1 ...
Kazuo Abe +3 more
doaj +1 more source
Dopamine agonist-resistant prolactinomas.
Journal of Neurosurgery, 2011 The authors' object in this paper was to review the definition, epidemiology, biology, resistance mechanisms, and treatment options for dopamine agonist-resistant prolactinomas (DARPs).
Michael C Oh, Manish K Aghi
semanticscholar +1 more source